Navigation Links
Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
Date:1/10/2011

MALVERN, Pa., Jan. 10, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today reported that preliminary fourth quarter 2010 total net revenue was $61.8 million, up 28.7% compared with $48.0 million in the fourth quarter of 2009.  For the full year 2010, preliminary total net revenue was $211.4 million, up 28.9% compared with $164.0 million in 2009.  

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

"We are energized by the significant progress that Auxilium made in 2010. We achieved record revenues for Testim®, launched XIAFLEX® in the U.S. for Dupuytren's contracture, received a positive CHMP opinion with our EU partner, Pfizer, for XIAFLEX for Dupuytren's contracture, and initiated XIAFLEX global phase III clinical trials for Peyronie's disease," said Armando Anido, Chief Executive Officer and President of Auxilium.  "As we look forward to 2011 and beyond, we expect Testim revenues to continue to grow and believe that the potential global market for XIAFLEX represents a blockbuster opportunity, which could provide sustainable long-term growth for the Company."

Preliminary Fourth Quarter 2010 Revenue DetailsAuxilium reported the following unaudited net revenues (all amounts in millions of dollars) for the quarter ended December 31, 2010: Quarter EndQuarter EndIncrease12/31/201012/31/2009(Decrease)Testim U.S. Revenue

$52.1$42.223.3%Testim Ex – U.S. & Contract Revenue

1.34.9(73.7%)Total Testim Revenue

$53.4$47.113.3%XIAFLEX U.S. Revenue

$7.3n/an/aXIAFLEX Contract Revenue

1.10.922.1%Total XIAFLEX Revenue

$8.4$0.9845.0%Total Worldwide Revenue

$61.8$48.028.7%Contract Revenues represent amortization of previously received upfront and milestone payments.

Preliminary 2010 Revenue DetailsAuxilium reported the following unaudited net revenues
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 STAAR Surgical Company ... and marketer of implantable lenses and delivery systems for ... quarter results and conference call with investors to July ... 2014.  The Company rescheduled the release date and conference ... services for Hideo Watanabe , President of STAAR ...
(Date:7/28/2014)... 2014 Reportbuyer.com has added a new market ... 2014-2018 https://www.reportbuyer.com/product/2225723/Global-Bone-Densitometers-Market-2014-2018.html ... a special type of X-ray test used to measure ... primarily to detect osteopenia or osteoporosis, diseases in which ... fractures is high. The purpose of bone densitometry is ...
(Date:7/28/2014)... -- June 28 th , 2014 – Oncolab, the ... cancer test, is making its AACC debut (booth #4051) at ... is a serum-based in vitro immunoassay, has been run for ... in the fight against cancer recurrence. Photo - ... million cancer survivors in the US alone, the race is ...
Breaking Medicine Technology:STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2
... - Amgen,(Nasdaq:AMGN) today presented the results from a ... safety of Aranesp(R) (darbepoetin alfa) for the,treatment of ... or radiotherapy ("the 103 study"). Aranesp is not,approved ... these patients. These,results were presented in an oral ...
... therapeutic approach for the treatment,of early and metastatic ... - AEterna,Zentaris Inc. , a global, pure play ... presented an,abstract outlining in vivo data for its ... at the American,Association for Cancer Research (AACR) Annual ...
Cached Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3
(Date:7/29/2014)... July 29, 2014 A simplified anesthesia procedure may ... the cause of airway obstruction in patients with severe ... Analgesia . , Dr. Joshua H. Atkins and Dr. ... their colleagues have developed a new "ramp control" anesthetic ... show the "obstructive anatomy" responsible for sleep apnea. The ...
(Date:7/29/2014)... CRN International has promoted a longtime executive ... Upton, an 11-year veteran at the radio marketing company, ... managing the day-to-day execution of all CRN client campaigns. ... all activities for CRN clients, which include some ... The department interfaces directly with clients, sets project timelines ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 1WorldSync ... world’s leading healthcare suppliers will utilize the Global ... product information network to share product information with ... other trading partners across their global supply chain. ... ID at B. Braun: "B. Braun serves customers ...
(Date:7/29/2014)... July 29, 2014 The Affordable Care ... model of all hospitals. Studies show that over 400 ... simple, easy, low cost tool that great hospitals use ... 20 to 25%. , Their secret? Debriefing - the ... at the end of an operational event. Debriefing is ...
(Date:7/29/2014)... Kathleen Doheny HealthDay Reporter , ... low risk of cardiovascular disease may be able to take ... without harming their hearts, according to a new study. ... hormone replacement therapy had harmful effects on the heart. But, ... hormone treatments, and much further past menopause. In ...
Breaking Medicine News(10 mins):Health News:New anesthesia technique helps show cause of obstruction in sleep apnea 2Health News:New anesthesia technique helps show cause of obstruction in sleep apnea 3Health News:CRN International Names New Director to Lead Client Services Department 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3
... the development of muscles.Da-Zhi Wang and other researchers of the ... the genes are among a recently discovered group of genes ... in the past few years have they been recognised as ... study authors said in an article that appeared in the ...
... experience with China, Pakistani pharmaceutical companies are keen to ... government // to relax the stringent visa norms. ... raw materials provided by the Chinese, apart from the ... problems with the Chinese, though their rates are cheaper ...
... Research Center has reported that maintaining the current recommended ... of cardiovascular disease. The researcher has asked the ... patients less than the recommended levels by aggressive blood ... is used to monitor the average amount of blood ...
... Baruch College has reported in his recent article that having ... . Dr. Brind has compiled data from recent studies of ... American Physicians and Surgeons. ,Professor Brind, ... that pregnancies leading to miscarriage or induced abortions does not ...
... obese people are in increased risk of developing eye ... Belkin and Zohar Habot-Wilner // , Goldschleger Eye Institute, ... and found that risk of developing eye problems are ... link between obesity and other chronic diseases and cancers. ...
... cholesterol can do to people. High-fat diets cause many patients' ... // to know what they consume. ,Now, new rules ... avoid trans fats, which plug arteries, and have been linked ... ,Trans fats are a result of manufacturers adding ...
Cached Medicine News:Health News:Pakistan drug companies seek trade ties with India 2Health News:Food labels to include information on trans fats in US 2Health News:Food labels to include information on trans fats in US 3
Spectrafuge 16M High speed microcentrifuge. High g-force for molecular biology applications. Brushless, maintenance-free motor. Easy to use control panel. Complete with 18 x 1.5/2.0 ml rotor. StripSp...
... two centrifuges -- the world's most popular ... in one reliable, quiet, compact unit. It ... two separate centrifuges!, For your microcentrifuge needs, ... supplies you with the MicroMB centrifuge, microcentrifuge ...
... Centrifuge 4-15C is designed to accommodate the deep-well ... necessary force of more than 5600 x g ... of both fixed-angle and swing-out rotors are available ... 15 ml, and 50 ml tubes, as well ...
... Model 5415D is an ideal workhorse for the ... of time and speed/g-force. , Product features ... , Compact 9 x 12-inch (W x D) ... a cold room , 24-place capacity ...
Medicine Products: